New Article information at Drug Development Technology New and updated information from Article listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New Article information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif Dinutuximab beta for the Treatment of Neuroblastoma http://www.drugdevelopment-technology.com/projects/dinutuximab-beta-for-the-treatment-of-neuroblastoma/ http://www.drugdevelopment-technology.com/projects/dinutuximab-beta-for-the-treatment-of-neuroblastoma/ Dinutuximab beta is an anti-GD2 monoclonal antibody indicated for the treatment of neuroblastoma in patients aged one year and above. Thu, 18 May 2017 23:00:00 GMT Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC) http://www.drugdevelopment-technology.com/projects/alunbrig-brigatinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/ http://www.drugdevelopment-technology.com/projects/alunbrig-brigatinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/ Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC). Tue, 16 May 2017 23:00:00 GMT Radicava (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) http://www.drugdevelopment-technology.com/projects/radicava-edaravone-for-the-treatment-of-amyotrophic-lateral-sclerosis-als/ http://www.drugdevelopment-technology.com/projects/radicava-edaravone-for-the-treatment-of-amyotrophic-lateral-sclerosis-als/ Radicava™ (edaravone) is a neuroprotective agent indicated for the treatment of amyotrophic lateral sclerosis (ALS). Sun, 14 May 2017 23:00:00 GMT Imfinzi (durvalumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC) http://www.drugdevelopment-technology.com/projects/imfinzi-durvalumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/ http://www.drugdevelopment-technology.com/projects/imfinzi-durvalumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/ Imfinzi™ (durvalumab) is a monoclonal antibody (mAb) indicated for the treatment of metastatic urothelial carcinoma (mUC). Sun, 07 May 2017 23:00:00 GMT Rydapt (midostaurin) for the Treatment of Acute Myeloid Leukaemia and Systemic Mastocytosis http://www.drugdevelopment-technology.com/projects/rydapt-midostaurin-for-the-treatment-of-acute-myeloid-leukaemia-and-systemic-mastocytosis/ http://www.drugdevelopment-technology.com/projects/rydapt-midostaurin-for-the-treatment-of-acute-myeloid-leukaemia-and-systemic-mastocytosis/ Rydapt® (midostaurin) is a multi-targeted inhibitor of multiple kinases including FMS-like tyrosine kinase 3 mutation-positive (FLT3+) and KIT approved for the treatment of acute myeloid leukaemia (AML) and three types of advanced systemic mastocytos… Tue, 02 May 2017 23:00:00 GMT April's top stories: NIAID's Phase II/IIb Zika vaccine trial, Boehringer's nintedanib in Phase III trial http://www.drugdevelopment-technology.com/features/featureaprils-top-stories-niaids-phase-iiiib-zika-vaccine-trial-boehringers-nintedanib-in-phase-iii-5800076/ http://www.drugdevelopment-technology.com/features/featureaprils-top-stories-niaids-phase-iiiib-zika-vaccine-trial-boehringers-nintedanib-in-phase-iii-5800076/ The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) began the Phase II/IIb clinical trial of a Zika vaccine, and Boehringer Ingelheim began patient enrolment in the Phase III PF-ILD trial of ninteda… Tue, 02 May 2017 23:00:00 GMT Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia http://www.drugdevelopment-technology.com/projects/ingrezza-valbenazine-for-the-treatment-of-tardive-dyskinesia/ http://www.drugdevelopment-technology.com/projects/ingrezza-valbenazine-for-the-treatment-of-tardive-dyskinesia/ Ingrezza (valbenazine) is first and only US Food and Drug Administration (FDA) approved vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with Tardive dyskinesia (TD). Mon, 17 Apr 2017 23:00:00 GMT Austedo (deutetrabenazine) for the Treatment of Chorea http://www.drugdevelopment-technology.com/projects/austedo-treatment-chorea/ http://www.drugdevelopment-technology.com/projects/austedo-treatment-chorea/ Austedo™ (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT 2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease (HD). Tue, 11 Apr 2017 23:00:00 GMT Zejula (niraparib) for the Treatment of Ovarian Cancer http://www.drugdevelopment-technology.com/projects/zejula-niraparib-for-the-treatment-of-ovarian-cancer/ http://www.drugdevelopment-technology.com/projects/zejula-niraparib-for-the-treatment-of-ovarian-cancer/ Zejula™ (Niraparib) is a poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor approved for the treatment of adult patients with ovarian cancer. Sun, 09 Apr 2017 23:00:00 GMT Xadago (safinamide) for the Treatment of Parkinson’s Disease (PD) http://www.drugdevelopment-technology.com/projects/xadago-safinamide-for-the-treatment-of-parkinsons-disease-pd/ http://www.drugdevelopment-technology.com/projects/xadago-safinamide-for-the-treatment-of-parkinsons-disease-pd/ Xadago® (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of Parkinson's disease. Tue, 04 Apr 2017 23:00:00 GMT March's top stories: Cancer Research UK's pancreatic cancer trials, Novartis' Cosentyx in psoriasis http://www.drugdevelopment-technology.com/features/featuremarchs-top-stories-cancer-research-uks-pancreatic-cancer-trials-novartis-cosentyx-in-psoriasis-5778534/ http://www.drugdevelopment-technology.com/features/featuremarchs-top-stories-cancer-research-uks-pancreatic-cancer-trials-novartis-cosentyx-in-psoriasis-5778534/ Cancer Research UK invested £10m in the PRECISION Panc project, including a network of clinical trials for the treatment of pancreatic cancer, and Novartis reported positive results from the extension A2302E1 trial of Cosentyx to modify the course of… Mon, 03 Apr 2017 23:00:00 GMT Translarna (ataluren) for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) http://www.drugdevelopment-technology.com/projects/translarna-ataluren-for-the-treatment-of-nonsense-mutation-duchenne-muscular-dystrophy-nmdmd/ http://www.drugdevelopment-technology.com/projects/translarna-ataluren-for-the-treatment-of-nonsense-mutation-duchenne-muscular-dystrophy-nmdmd/ Translarna™ (ataluren) is a protein restoration therapy indicated for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The drug was developed by PTC Therapeutics. Sun, 02 Apr 2017 23:00:00 GMT Tresiba (insulin degludec) for the Treatment of Type 1 and Type 2 Diabetes http://www.drugdevelopment-technology.com/projects/tresiba-insulin-degludec-for-the-treatment-of-type-1-and-type-2-diabetes/ http://www.drugdevelopment-technology.com/projects/tresiba-insulin-degludec-for-the-treatment-of-type-1-and-type-2-diabetes/ Tresiba (insulin degludec) is the first, long-acting, human insulin indicated for the treatment of Type 1 and Type 2 diabetes. The drug was discovered and developed by Novo Nordisk. Mon, 27 Mar 2017 23:00:00 GMT Kisqali® (ribociclib) for the Treatment of HR+/HER2- Metastatic Breast Cancer http://www.drugdevelopment-technology.com/projects/kisqali-ribociclib-for-the-treatment-of-hrher2--metastatic-breast-cancer/ http://www.drugdevelopment-technology.com/projects/kisqali-ribociclib-for-the-treatment-of-hrher2--metastatic-breast-cancer/ Formerly known as LEE011, Kisqali® (ribociclib) is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor indicated for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer i… Wed, 15 Mar 2017 14:04:00 GMT Qtern (dapagliflozin and saxagliptin) for the Treatment of Type 2 Diabetes http://www.drugdevelopment-technology.com/projects/qtern-dapagliflozin-and-saxagliptin-for-the-treatment-of-type-2-diabetes/ http://www.drugdevelopment-technology.com/projects/qtern-dapagliflozin-and-saxagliptin-for-the-treatment-of-type-2-diabetes/ Qtern (dapagliflozin and saxagliptin) is a combination drug with sodium/glucose cotransporter (SGLT) 2 and dipeptidyl peptidase 4 (DPP-4) inhibitors indicated for the treatment of type 2 diabetes. Thu, 09 Mar 2017 00:00:00 GMT February's top stories: Merck's Phase III HIV-1 trial results, NIH's Phase I AGS-v vaccine trial http://www.drugdevelopment-technology.com/features/featurefebruarys-top-stories-mercks-phase-iii-hiv-1-trial-results-nihs-phase-i-ags-v-vaccine-trial-5757057/ http://www.drugdevelopment-technology.com/features/featurefebruarys-top-stories-mercks-phase-iii-hiv-1-trial-results-nihs-phase-i-ags-v-vaccine-trial-5757057/ Merck reported positive results from the Phase III trial of its non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine (MK-1439) for the treatment of patients with HIV-1 infection, and NIH's NIAID initiated a Phase I trial of vaccine AGS-v… Tue, 07 Mar 2017 00:00:00 GMT Alecensa (alectinib) for Treatment of ALK-positive Non-small Cell Lung Cancer http://www.drugdevelopment-technology.com/projects/alecensa-alectinib-for-treatment-of-alk-positive-non-small-cell-lung-cancer-nsclc/ http://www.drugdevelopment-technology.com/projects/alecensa-alectinib-for-treatment-of-alk-positive-non-small-cell-lung-cancer-nsclc/ Alecensa (alectinib) is a kinase inhibitor intended for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Thu, 02 Mar 2017 11:47:00 GMT Emflaza (deflazacort) for the Treatment of Duchenne Muscular Dystrophy http://www.drugdevelopment-technology.com/projects/emflaza-deflazacort-for-the-treatment-of-duchenne-muscular-dystrophy/ http://www.drugdevelopment-technology.com/projects/emflaza-deflazacort-for-the-treatment-of-duchenne-muscular-dystrophy/ Emflaza™ (deflazacort) is the first glucocorticoid drug approved in the US for the treatment of patients aged five and older suffering from duchenne muscular dystrophy (DMD). The drug was discovered and developed by Marathon Pharmaceuticals. Fri, 17 Feb 2017 00:00:00 GMT Symbicort (budesonide and formoterol) for the Treatment of Asthma http://www.drugdevelopment-technology.com/projects/symbicort-budesonide-and-formoterol-for-the-treatment-of-asthma/ http://www.drugdevelopment-technology.com/projects/symbicort-budesonide-and-formoterol-for-the-treatment-of-asthma/ Symbicort (budesonide and formoterol) is an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) indicated for the treatment of asthma in paediatric patients aged between six and 12 years. The drug was discovered and developed by AstraZe… Fri, 17 Feb 2017 00:00:00 GMT January's top stories: TG Therapeutics' Phase II trial, antidepressant hip fracture risk http://www.drugdevelopment-technology.com/features/featurejanuarys-top-stories-tg-therapeutics-has-begun-its-phase-ii-investigator-and-calcimedica-has-initiated-the-phase-i-safety-studies-5731135/ http://www.drugdevelopment-technology.com/features/featurejanuarys-top-stories-tg-therapeutics-has-begun-its-phase-ii-investigator-and-calcimedica-has-initiated-the-phase-i-safety-studies-5731135/ TG Therapeutics began its Phase II investigator initiated trial of TGR-1202 in combination with ibrutinib to treat Diffuse Large B-cell Lymphoma (DLBCL), and a study suggested that antidepressant usage increases the risk of hip fracture. Drugdevelopm… Mon, 06 Feb 2017 00:00:00 GMT